Vaccine

Keyphrases

Publications

volume 42, number 9, 2024

Philippe St-Louis, Clément Martin, Vinay Khatri, Steve Bourgault, Denis Archambault
Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice. Vaccine 42 (9) (2024)
Jessabelle E Basa, Ralf Clemens, Sue Ann Costa Clemens, Martin Nicholson
Landscaping analysis of immunization progress and program structures in selected middle income Southeast Asian countries. Vaccine 42 (9) (2024)
W H S Wong, D L Leung, K M Yip, H K So, J S Rosa Duque, Y L Lau
Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong. Vaccine 42 (9) (2024)
Doug H Cheung, Siyu Chen, Yuan Fang, Fenghua Sun, Qingpeng Zhang, Fuk-Yuen Yu, Phoenix K H Mo, Zixin Wang
Influences of mpox disease perceptions, sources and contents of information exposure on mpox vaccine uptake among gay, bisexual, and other men who have sex with men in Hong Kong, China. Vaccine 42 (9) (2024)
Myron J Levin, Adit A Ginde, D Scott Schmid, Nancy Lang, Jennifer Canniff, Robert S Schwartz, Adriana Weinberg
Effect of high dose vitamin D supplementation on subsequent immune responses to administration of the live herpes zoster vaccine to long-term care residents. Vaccine 42 (9) (2024)
Pedro L Moro, Grace Carlock, Nimita Fifadara, Tei Habenicht, Bicheng Zhang, Penelope Strid, Paige Marquez
Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023. Vaccine 42 (9) (2024)
Aurélie De Waele, Greet Hendrickx, Sara Valckx, Àngela Domínguez, Diana Toledo, Jesús Castilla, José Tuells, Pierre Van Damme
The Vaccine Training Barometer: Assessing healthcare providers' confidence to answer vaccine-related questions and their training needs. Vaccine 42 (9) (2024)
Lixian Su, Xiaofeng Zhou, Weijun Peng, Jingwei Luo, Qiaoxiang Lin, Lizhen Liu, Jian Lin, Shufen Lin, Kechun Zhang, Hongbiao Chen, Muyun Liu
Investigation on the correlation factors of positive Streptococcus pneumoniae antibody and IgG antibody level of Streptococcus pneumoniae in the elderly over 60 years old in Shenzhen. Vaccine 42 (9) (2024)
Sarah G Yashar-Gershman, Alix T Rosenberg, Muskaan Sawhney, Maria Fernanda Machicao, Howard R Moskowitz, Henry H Bernstein
Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care. Vaccine 42 (9) (2024)
Michele Kohli, Michael Maschio, Amy Lee, Ataru Igarashi
Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine. Vaccine 42 (9) (2024)
Lizet Opmeer, Isabella Gazzoli, Mónika Ballmann, Marieke Willemsen, Gerben P Voshol, Magda Grudniewska-Lawton, Menzo Havenga, Christopher Yallop, Ahd Hamidi, Gert Gillissen, Wilfried A M Bakker
High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains. Vaccine 42 (9) (2024)
Gerald Etapelong Sume, Quamrul Hasan, Abigail Shefer, Louise Henaff, Kathleen F Cavallaro, Catherine B Tencza, Stephen C Hadler, Ndiaye Sidy, Parwiz Sardar, Benjamin M Kagina, Yvan Hutin
Region-wide assessment of National Immunization Technical Advisory Groups (NITAGs) using the NITAG Maturity Assessment Tool (NMAT) - Experience from the Eastern Mediterranean Region of the World Health Organization, 2023. Vaccine 42 (9) (2024)
Jonathan Fix, T Christopher Mast, Katherine Smith, Nicole Baker
Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373). Vaccine 42 (9) (2024)
Kota Senpuku, Chikako Kataoka-Nakamura, Yuta Kunishima, Toshiro Hirai, Yasuo Yoshioka
An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice. Vaccine 42 (9) (2024)
Alice Shijia Yan, Neil Jay Sehgal
Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S. Vaccine 42 (9) (2024)
Ninaad Lasrado, Annika Rössler, Marjorie Rowe, Ai-Ris Y Collier, Dan H Barouch
Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1. Vaccine 42 (9) (2024)
Greta Sirek, Sciaska Ulysse, Marie Jacques Toussaint, Chisa Nosamiefan, Ludwige Desrosiers, Mia Chandler, Rosalind Ramsey-Goldman, Dieufort J Fleurissaint, Candace H Feldman
A community-engaged approach to translate a Vaccine Hesitancy Scale into Haitian Creole. Vaccine 42 (9) (2024)
Lu Meng, LaTreace Harris, Lauren Shaw, Hoody Lymon, Hannah Reses, Jeneita Bell, Peng-Jun Lu, Lynn Gibbs-Scharf, Terence Chorba
Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged ≥ 12 years, United States, August 2021-October 2022. Vaccine 42 (9) (2024)
Monique Luisi, Mugur V Geana, Jun Pei
Pandemic antecedents - Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination. Vaccine 42 (9) (2024)
Khalequ Zaman, Anne E Schuind, Samuel Adjei, Kalpana Antony, John J Aponte, Patrick By Buabeng, Firdausi Qadri, Troy J Kemp, Lokman Hossain, Ligia A Pinto, Kristen Sukraw, Niranjan Bhat, Tsiri Agbenyega
Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial. Vaccine 42 (9) (2024)
Ashley C Beavis, Krista Dienger-Stambaugh, Kelsey Briggs, Zhenhai Chen, Mathew Abraham, Paul Spearman, Biao He
A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice. Vaccine 42 (9) (2024)
Tanjila Hasan, Naomi Shimoda, Shu Nakamura, Barbara A Fox, David J Bzik, Nanako Ushio-Watanabe, Yoshifumi Nishikawa
Protective efficacy of recombinant Toxoplasma gondii dense granule protein 15 against toxoplasmosis in C57BL/6 mice. Vaccine 42 (9) (2024)
Monika Raethke, Florence van Hunsel, Nicoletta Luxi, Thomas Lieber, Chiara Bellitto, Erik Mulder, Francesco Ciccimarra, Fabio Riefolo, Nicolas H Thurin, Debabrata Roy, Kathryn Morton, Felipe Villalobos, Francisco Batel Marques, Andreea Farcas, Simona Sonderlichová, Svetlana Belitser, Olaf Klungel, Gianluca Trifirò, Miriam C Sturkenboom
Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study. Vaccine 42 (9) (2024)
Annamária Huber, Eszter Kovács, Andrea Horváth, Judit Sahin-Tóth, Ákos Kaptás, Emese Juhász, Katalin Kristóf, Orsolya Dobay
Prevalence, serogroup distribution and risk factors of Neisseria meningitidis carriage in high school and university students in Hungary. Vaccine 42 (9) (2024)
Davood Yadegarynia, Amirreza Keyvanfar, Hossein Keyvani, Shabnam Tehrani, Shahnaz Sali, Sara Abolghasemi
Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial. Vaccine 42 (9) (2024)
Igor Krasilnikov, Artur Isaev, Milana Djonovic, Alexander Ivanov, Ekaterina Romanovskaya-Romanko, Marina Stukova, Vitaly Zverev
Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity. Vaccine 42 (9) (2024)
K Faksova, D Walsh, Y Jiang, J Griffin, A Phillips, A Gentile, J C Kwong, K Macartney, M Naus, Z Grange, S Escolano, G Sepulveda, A Shetty, A Pillsbury, C Sullivan, Z Naveed, N Z Janjua, N Giglio, J Perälä, S Nasreen, H Gidding, P Hovi, T Vo, F Cui, L Deng, L Cullen, M Artama, H Lu, H J Clothier, K Batty, J Paynter, H Petousis-Harris, J Buttery, S Black, A Hviid
COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine 42 (9) (2024)
Kenneth W Moffett, Kate Seserman, Katherine A Margolis, Elissa C Kranzler, Michael C Marshall, Heather Dahlen, Jae-Eun C Kim, Benjamin Denison, Blake Hoffman, Daphney Dupervil, Kathleen Yu, Leah Hoffman
Differences in social media use by COVID-19 vaccination status. Vaccine 42 (9) (2024)
Jiajie Liu, Qi Qi, Yu Liu, Ping Ni, Xuhua Zhan, Ying Bao, Yinqiao Li, Lijin Liu, Qing Yang, Yi Liu, Kai Zhang
A paired measles-rubella catch-up campaign in Sichuan China to stop an outbreak and strengthen local immunization programs. Vaccine 42 (9) (2024)
Chia-Ying Wu, Shao-En Kao, Yung-Chieh Tseng, Jen-Tzu Hou, Li-Yang Wu, Juine-Ruey Chen
Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine. Vaccine 42 (9) (2024)
Ladan Hashemi, Maryam Ghasemi, Allen Bartley, John Fenaughty, Maryam Pirouzi, Cameron Grant
Migration and infant immunization timeliness in New Zealand: Evidence from the Growing Up in New Zealand study. Vaccine 42 (9) (2024)
Lore Merdrignac, Fatima Aït El Belghiti, Elisabetta Pandolfi, Lesly Acosta, Kateřina Fabiánová, Adele Habington, Manuel García Cenoz, Håkon Bøås, Julie Toubiana, Alberto E Tozzi, Iolanda Jordan, Jana Zavadilová, Niam O'Sullivan, Ana Navascués, Elmira Flem, Ilena Croci, Mireia Jané, Pavla Křížová, Suzanne Cotter, Leticia Fernandino, Terese Bekkevold, Carmen Muñoz-Almagro, Sabrina Bacci, Piotr Kramarz, Esther Kissling, Camelia Savulescu, null null, null null
Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 2019. Vaccine 42 (9) (2024)
Yu-Wen Su, Yuan-Zheng Qiu, Yuan-Hui Wang, Yan Xu, Chao-Chao Huang, Qing Zhang, Chang Su, Jun-Heng Ma, Wen Liu, Yan Liu, Mao-Sheng Zhao, Han-Yu Yang, Chun-Lei Li, Xiang Lu
Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial. Vaccine 42 (9) (2024)
Hannah J Morgan, Hazel J Clothier, Gonzalo Sepulveda Kattan, James H Boyd, Jim P Buttery
Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis. Vaccine 42 (9) (2024)
Rapeepat Tandavanitj, Chayanee Setthapramote, Giuditta De Lorenzo, Ricardo Sanchez-Velazquez, Jordan J Clark, Mara Rocchi, Colin McInnes, Alain Kohl, Arvind H Patel
Virus-like particles of louping ill virus elicit potent neutralizing antibodies targeting multimers of viral envelope protein. Vaccine 42 (9) (2024)
Nicholas Brousseau, Marie-Elen Angers-Goulet, Robin Bastien, Lingyun Ye, Manish Sadarangani, Scott A Halperin
Vaccination during pregnancy and modulation of IgG response to pertussis vaccines in infants: The impact of different vaccine formulations. Vaccine 42 (9) (2024)
Ivette Maldonado, Nicolas Rodríguez Niño, Carlos F Valencia, Daniela Ortiz, Nathalia Ayala, Liz D'silva, Santiago Castro Villarreal, Diego Salazar, Catalina Lozano, Daniela Angulo
Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia. Vaccine 42 (9) (2024)
Jaikin E Harrell, Chad J Roy, John S Gunn, James B McLachlan
Current vaccine strategies and novel approaches to combatting Francisella infection. Vaccine 42 (9) (2024)
Joshua Karras, Mia Harrison, Maryke Steffens, Ikram Abdi, Holly Seale
"COVID is a huge jigsaw puzzle that I am trying to make sense of myself": Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adults. Vaccine 42 (9) (2024)
Peter B Gilbert, Youyi Fong, Nima S Hejazi, Avi Kenny, Ying Huang, Marco Carone, David Benkeser, Dean Follmann
Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial. Vaccine 42 (9) (2024)
Rodolfo F Marques, Alba M Gimenez, Otávia Caballero, Andrew Simpson, Andres M Salazar, Rogerio Amino, Steven Godin, Ricardo T Gazzinelli, Irene S Soares
Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol®) as adjuvant. Vaccine 42 (9) (2024)
K Faksova, D Walsh, Y Jiang, J Griffin, A Phillips, A Gentile, J C Kwong, K Macartney, M Naus, Z Grange, S Escolano, G Sepulveda, A Shetty, A Pillsbury, C Sullivan, Z Naveed, N Z Janjua, N Giglio, J Perälä, S Nasreen, H Gidding, P Hovi, T Vo, F Cui, L Deng, L Cullen, M Artama, H Lu, H J Clothier, K Batty, J Paynter, H Petousis-Harris, J Buttery, S Black, A Hviid
COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine 42 (9) (2024)
Xiaoxia Duan, Liangzhi Zhang, Ling Ding, Chaoyong Zhang, Zhenhua Chen, Yue Cheng, Xiao Wang, Hongxia Peng, Xueqin Tang, Xueling Ren, Juan Liao, Sufei Yang, Yu Zhu, Wei Luo, Yilan Zeng, Ping Yuan, Lu Long
Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection. Vaccine 42 (9) (2024)
Tracy Evans-Gilbert, J Peter Figueroa, Pablo Bonvehí, Mario Melgar, Daniel Stecher, Renato Kfouri, Greta Munoz, Rakesh Bansie, Renato Valenzuela, Eduardo Verne, Daniel Salas, N Jennifer Sanwogou
Establishing priorities to strengthen National Immunization Technical Advisory Groups in Latin America and the Caribbean. Vaccine 42 (9) (2024)
Gerald Etapelong Sume, Quamrul Hasan, Abigail Shefer, Louise Henaff, Kathleen F Cavallaro, Catherine B Tencza, Stephen C Hadler, Ndiaye Sidy, Parwiz Sardar, Benjamin M Kagina, Yvan Hutin
Region-wide assessment of National Immunization Technical Advisory Groups (NITAGs) using the NITAG Maturity Assessment Tool (NMAT) - Experience from the Eastern Mediterranean Region of the World Health Organization, 2023. Vaccine 42 (9) (2024)
B C Gärtner, A Kwetkat, D Beier, K Wahle, K J Schmidt, T F Schwarz
Reply to letter to editor by Yin et al. Vaccine 42 (9) (2024)
Dongxuan Chen, Benjamin J Cowling, Kylie E C Ainslie, Yun Lin, Jessica Y Wong, Eric H Y Lau, Peng Wu, Joshua Nealon
Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong. Vaccine 42 (9) (2024)
Weiyu Zhou, Xiang Guo, Jia Lu, Xinyue Lu, Xiaoya Fu, Yihan Lu
Parental willingness to accept and pay human papillomavirus vaccine for boys aged 9-14 in a metropolis area of China: Evidence for developing a vaccination strategy. Vaccine 42 (9) (2024)
B C Gärtner, A Kwetkat, D Beier, K Wahle, K J Schmidt, T F Schwarz
Reply to letter to editor by Yin et al. Vaccine 42 (9) (2024)
Hannah J Morgan, Hazel J Clothier, Gonzalo Sepulveda Kattan, James H Boyd, Jim P Buttery
Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis. Vaccine 42 (9) (2024)